Novel ASAP1-USP6, FAT1-USP6, SAR1A-USP6, and TNC-USP6 fusions in primary aneurysmal bone cyst.
Daja ŠekoranjaAndrej ZupanBlaž MavčičDavid MartinčičVladka SalapuraŽiga SnojAna K Limpel NovakJože PižemPublished in: Genes, chromosomes & cancer (2020)
Aneurysmal bone cyst (ABC) is a benign but locally aggressive neoplasm, with a tendency for local recurrence. In contrast to other bone tumors with secondary cystic change, ABC is characterized by USP6 gene rearrangement. There is a growing list of known USP6 fusion partners, characterization of which has been enabled with the advent of next-generation sequencing (NGS). The list of known fusion partners includes CDH11, CNBP, COL1A1, CTNNB1, EIF1, FOSL2, OMD, PAFAH1B1, RUNX2, SEC31A, SPARC, STAT3, THRAP3, and USP9X. Using NGS, we analyzed a series of 11 consecutive ABCs and identified USP6 fusions in all cases, providing further evidence that USP6 fusions are universally present in primary ABCs. We identified four novel fusion partners in five ABCs and confirmed them by RT-PCR and Sanger sequencing, ASAP1, FAT1, SAR1A, and TNC (in two cases). Because of high sensitivity and specificity, detection of a USP6 fusion by NGS may assist in differentiating between ABC and its mimics, especially in small biopsy samples when a definite diagnosis cannot be achieved on morphological grounds alone. Further studies with a large number of cases and follow-up are needed to determine whether different fusion partners are associated with specific clinical and pathologic features of ABCs.
Keyphrases
- bone mineral density
- adipose tissue
- gene expression
- copy number
- magnetic resonance
- soft tissue
- computed tomography
- squamous cell carcinoma
- dna methylation
- hiv testing
- magnetic resonance imaging
- postmenopausal women
- contrast enhanced
- ultrasound guided
- lymph node
- low grade
- antiretroviral therapy
- human immunodeficiency virus
- free survival
- bone regeneration
- locally advanced